Trials / Completed
CompletedNCT00824512
Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia. A 3 Month, Phase II, Randomised, Double Blind, Placebo Controlled, Parallel Group Clinical Study.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 12 Years – 22 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this protocol is to determine the efficacy of EGb 761 120 mg bid versus placebo in patients suffering from Friedreich Ataxia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EGb 761 120 mg | EGb 761® 120 mg bid, orally for 12 to 14 weeks |
| DRUG | Placebo | Placebo 1 tablet BID, orally for 12 to 14 weeks |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2009-01-16
- Last updated
- 2020-04-07
- Results posted
- 2013-05-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00824512. Inclusion in this directory is not an endorsement.